Northwest Biotherapeutics says data 'very promising' for personalized brain cancer vaccine

By Elaine Rigoli

Tampa, Fla., May 3 - Northwest Biotherapeutics will present updated data from the second phase 1 clinical trial on patients who have received DCVax-Brain, a personalized therapeutic cancer vaccine, at the 12th annual meeting of the International Society for Cellular Therapy.

The meeting runs from May 4 to May 7 in Berlin.

Updated survival and progression data, accumulated through April, will be presented on a vaccine that continues to produce very promising results, the company said in a news release.

The phase 1 clinical trial of DCVax-Brain involved patients with Glioblastoma multiforme, one of the deadliest forms of brain cancer.

As previously reported in February, the following findings had been observed and reported for the DCVax-Brain trial:

• Eight of 10 patients still alive, with median survival of 20.5 months and continuing;

• Four of 10 patients survived over 30 months and were continuing, and five of 10 patients survived over 24 months and were continuing;

• Eight of 10 patients surpassed the historical control median survival of 15 months, with other patients still continuing toward that point;

• Survival times to date ranged from 11.2 months to 39.0 months, and continuing;

• Five of 10 patients continued to show no signs of cancer, with median follow-up time of 32 months;

• Median time to progression (i.e., tumor recurrence) was 14.7 months and continuing;

• Nine of 10 patients had surpassed the historical median time to progression of eight months.

Based in Bothell, Wash., Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.